Apimeds Pharmaceuticals US, Inc. announced that it will effect a 1-for-10 reverse stock split of its common stock. The company expects to file the necessary Charter Amendment with the Delaware Secretary of State on or about July 23, 2026, with the split becoming effective at 12:01 a.m. Eastern Time on July 24, 2026. Common stock is expected to trade on a split-adjusted basis on the NYSE American under the symbol "APUS" starting July 24, 2026, with a new CUSIP number of 03771D201. This replaces a previously announced effective date of March 26, 2026. The company operates in the pharmaceutical industry and develops medical treatments.
